Neurocentria a late-stage biotech company has received approval to initiate a pivotal phase 2b/3 clinical trial of its NRCT-101SR compared with inactive placebo among adult patients with ADHD.
PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.